CT
Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
$0.58 +1.47% (+$0.01)
1M -8.01%
Market Cap $6.37M
P/E Ratio -
Div. Yield -
ROE 71.58%
Bulios Fair Price
$0.77
33.1% upside
Current Price
$0.58
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CTXR is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/B 0.10x
P/S 0.90x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 13.07%
FCF growth N/A
EPS growth N/A
Profitability
18 /100
Weak Op. margin 857.00%
Gross margin 44.19%
FCF margin 444.69%
Quality
1 /100
Poor ROA 34.68%
ROIC 67.29%
Asset turnover 0.05x
Debt
52 /100
Moderate Int. coverage -947.30x
Debt/Equity 0.11x
Current ratio 0.84x
Stability
63 /100
Moderate Profitable years 0
Beta 1.00x
EPS volatility 26.69%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CTXR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Leonard L. Mazur
Employees
23
Headquarters
Cranford
Upcoming events
17 DEC
Earnings
Upcoming earnings report
22 DEC
Earnings
Upcoming earnings report